Form 4: Cidara Director's Options Cashed Out in Merck Merger

Cidara Therapeutics director Carin Canale-Theakston's stock options were converted to cash following the company's acquisition by Merck Sharp & Dohme LLC.

Summary

• Cidara Therapeutics, Inc. (CDTX) was acquired by Merck Sharp & Dohme LLC (Merck) through its wholly-owned subsidiary, Caymus Purchaser, Inc.
• The merger was completed on January 7, 2026, following a tender offer for all outstanding common and Series A preferred stock of Cidara.
• As a result of the merger, Cidara Therapeutics, Inc. became a wholly-owned subsidiary of Merck.
• Director Carin Canale-Theakston's outstanding stock options became fully vested and exercisable immediately prior to the merger's effective time.
• These options were subsequently cancelled and converted into a cash payment.
• The cash payment for each option was calculated as the product of the total number of Common Shares subject to such option and the excess of the merger price of $221.50 per Common Share over the option's exercise price.
• A 1-for-20 reverse stock split, effective April 24, 2024, adjusted the reported exercise prices and number of securities underlying the options.

Sentiment

Score: 7

Explanation: The filing reports a completed merger and the cash-out of director options, which is a positive liquidity event for the option holder. While it signifies the end of Cidara as an independent entity, the transaction itself is a successful outcome for its equity holders. The sentiment is neutral to positive as it's a factual report of a completed, beneficial transaction for the reporting person.

Positives

• Director Carin Canale-Theakston realized cash value from her stock options due to the merger, providing a liquidity event.
• The merger provided a clear exit strategy and liquidity for option holders, as all eligible options were converted to cash.
• All outstanding options became fully vested and exercisable upon the merger, ensuring all eligible options were converted.

Negatives

• Cidara Therapeutics, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Merck.
• Existing stock options were cancelled, meaning no future upside potential from these specific options for the director beyond the merger price.

Future Outlook

The filing primarily reports a past transaction related to a completed merger. As Cidara Therapeutics is now a wholly-owned subsidiary of Merck, its independent future outlook as a public company is no longer applicable. The future outlook for the acquired assets and operations will be integrated into Merck's overall strategy.

Management Comments

• The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
• Pursuant to the Agreement and Plan of Merger, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised, was cancelled and converted into the right to receive cash.

Industry Context

This transaction reflects a common trend in the biotechnology and pharmaceutical sectors where larger, established companies like Merck acquire smaller, innovative firms like Cidara Therapeutics to expand their pipeline, gain access to new technologies, or consolidate market share. Such mergers often provide liquidity events for shareholders and option holders of the acquired company, while the acquirer integrates the target's assets into its broader R&D and commercialization strategies.

Comparison to Industry Standards

• The acquisition of Cidara Therapeutics by Merck is consistent with the pharmaceutical industry's ongoing consolidation, where major players frequently acquire smaller biotech firms to bolster their drug pipelines. For example, similar acquisitions include Pfizer's acquisition of Seagen for $43 billion to enhance its oncology portfolio, or AbbVie's acquisition of Allergan for $63 billion to diversify its therapeutic areas.
• The cash-out of stock options upon merger completion is a standard practice in M&A, ensuring that employees and directors are compensated for their equity holdings based on the agreed-upon acquisition price, similar to how options were handled in Gilead Sciences' acquisition of Immunomedics for $21 billion.
• The 1-for-20 reverse stock split prior to the merger is a common corporate action often undertaken by companies to increase their share price and meet listing requirements or make the stock more attractive for institutional investors, as seen with numerous small-cap biotechs before significant corporate events.

Stakeholder Impact

• Shareholders of Cidara Therapeutics, Inc. received $221.50 per Common Share in the tender offer, providing a liquidity event.
• Option holders, including Director Carin Canale-Theakston, had their options fully vested and converted to cash based on the merger price, realizing value.
• Employees of Cidara Therapeutics, Inc. are now part of Merck Sharp & Dohme LLC, potentially impacting their roles, benefits, and corporate culture.
• Customers and suppliers of Cidara Therapeutics, Inc. will now interact with a Merck subsidiary, which may lead to changes in product offerings, support, or supply chain dynamics.

Next Steps

• Cidara Therapeutics, Inc. will continue to operate as a wholly-owned subsidiary of Merck Sharp & Dohme LLC.
• Merck will integrate Cidara's assets and operations into its broader corporate structure.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Merck, Merger, Acquisition, Stock Options, Form 4, Insider Transaction, Biotechnology, Pharmaceuticals, Tender Offer, Reverse Stock Split